Paul Tudor Jones's BCRX Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 195,128 shares of BioCryst Pharmaceuticals, Inc. (BCRX) worth $1.95 M, representing 0.00% of the portfolio. First purchased in 2015-Q2, this long-term strategic position has been held for 35 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in BCRX, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2026, adding 195,128 shares. Largest reduction occurred in Q1 2024, reducing 209,905 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's BioCryst Pharmaceuticals (BCRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly BioCryst Pharmaceuticals (BCRX) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +195,128 | New Buy | 195,128 | $10.00 |
| Q1 2026 | -114,541 | Sold Out | 0 | $0.00 |
| Q4 2025 | +16,366 | Add 16.67% | 114,541 | $7.80 |
| Q3 2025 | -80,909 | Reduce 45.18% | 98,175 | $7.59 |
| Q2 2025 | +74,042 | Add 70.49% | 179,084 | $8.96 |
| Q1 2025 | +5,592 | Add 5.62% | 105,042 | $7.50 |
| Q4 2024 | +99,450 | New Buy | 99,450 | $7.52 |
| Q3 2024 | -103,002 | Sold Out | 0 | $0.00 |
| Q2 2024 | +103,002 | New Buy | 103,002 | $6.18 |
| Q1 2024 | -209,905 | Sold Out | 0 | $0.00 |
| Q4 2023 | +115,470 | Add 122.27% | 209,905 | $5.99 |
| Q3 2023 | +17,773 | Add 23.18% | 94,435 | $7.08 |
| Q2 2023 | +76,662 | New Buy | 76,662 | $7.04 |
| Q4 2022 | -92,879 | Sold Out | 0 | $0.00 |
| Q3 2022 | +68,818 | Add 286.01% | 92,879 | $12.60 |
| Q2 2022 | +24,061 | New Buy | 24,061 | $10.60 |
| Q4 2021 | -131,066 | Sold Out | 0 | $0.00 |
| Q3 2021 | +68,168 | Add 108.38% | 131,066 | $14.37 |
| Q2 2021 | +4,981 | Add 8.60% | 62,898 | $15.80 |
| Q1 2021 | +57,917 | New Buy | 57,917 | $10.17 |
| Q2 2020 | -49,102 | Sold Out | 0 | $0.00 |
| Q1 2020 | -104,005 | Reduce 67.93% | 49,102 | $2.00 |
| Q4 2019 | +93,959 | Add 158.85% | 153,107 | $3.45 |
| Q3 2019 | +22,281 | Add 60.44% | 59,148 | $2.86 |
| Q2 2019 | +36,867 | New Buy | 36,867 | $3.80 |
| Q4 2017 | -102,494 | Sold Out | 0 | $0.00 |
| Q3 2017 | +60,566 | Add 144.45% | 102,494 | $5.24 |
| Q2 2017 | +41,928 | New Buy | 41,928 | $5.56 |
| Q4 2016 | -11,137 | Sold Out | 0 | $0.00 |
| Q3 2016 | -5,550 | Reduce 33.26% | 11,137 | $4.40 |
| Q2 2016 | -108,901 | Reduce 86.71% | 16,687 | $2.82 |
| Q1 2016 | +114,403 | Add 1022.83% | 125,588 | $2.83 |
| Q4 2015 | -18,350 | Reduce 62.13% | 11,185 | $10.28 |
| Q3 2015 | +16,227 | Add 121.93% | 29,535 | $11.41 |
| Q2 2015 | +13,308 | New Buy | 13,308 | $14.95 |
Paul Tudor Jones's BioCryst Pharmaceuticals Investment FAQs
Paul Tudor Jones first purchased BioCryst Pharmaceuticals, Inc. (BCRX) in Q2 2015, acquiring 13,308 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held BioCryst Pharmaceuticals, Inc. (BCRX) for 35 quarters since Q2 2015.
Paul Tudor Jones's largest addition to BioCryst Pharmaceuticals, Inc. (BCRX) was in Q2 2026, adding 195,128 shares worth $1.95 M.
According to the latest 13F filing for Q2 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 195,128 shares of BioCryst Pharmaceuticals, Inc. (BCRX), valued at approximately $1.95 M.
As of the Q2 2026 filing, BioCryst Pharmaceuticals, Inc. (BCRX) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in BioCryst Pharmaceuticals, Inc. (BCRX) was 209,905 shares, as reported at the end of Q4 2023.